News

Adarx to use $200M in financing to advance its clinical programs

Adarx Pharmaceuticals will use $200 million in oversubscribed Series C financing to further develop its clinical programs — including ADX-324, its treatment candidate for hereditary angioedema (HAE) — the clinical-stage biotechnology company announced. The funding round was led by Bain Capital Life Sciences and TCGX, an investment firm…

FDA approves new generic version of Firazyr for HAE

The U.S. Food and Drug Administration (FDA) has approved a new generic version of Firazyr (icatibant injection) for hereditary angioedema (HAE), Aurobindo Pharma announced in a press release. Like the brand-name medication, the new generic is indicated to treat acute swelling attacks of HAE in adults 18…

Patient enrollment for deucrictibant CHAPTER-1 trial completed

Pharvaris has completed patient enrollment for its proof-of-concept CHAPTER-1 clinical trial that will evaluate the safety and effectiveness of deucrictibant as a prophylactic, or preventive, treatment for adults with hereditary angioedema (HAE). While the global Phase 2 CHAPTER-1 study (NCT05047185) is still on hold in the U.S.,…

Possible treatment of ACE inhibitor-induced angioedema symptoms ID’d

Treatment with tranexamic acid may ease symptoms and prevent intubation in people who develop angioedema after receiving certain high blood pressure medications called angiotensin-converting enzyme (ACE) inhibitors, a review of published studies shows. The findings also suggest tranexamic acid may be more advantageous than other therapies currently used to…

Rare case of NEAE reported after COVID-19 vaccination

A 26-year-old woman developed a rare case of non-episodic angioedema associated with eosinophilia (NEAE) following her second dose of the Pfizer-BioNTech COVID-19 vaccine, according to a study from Japan. Eosinophilia refers to higher-than-normal levels of a type of immune cells called eosinophils. Her NEAE symptoms were resolved completely two months…

Company chosen to commercialize HAE medicine Orladeyo in Turkey

BioCryst Pharmaceuticals is teaming up with Er-Kim Pharmaceuticals to commercialize Orladeyo (berotralstat) in Turkey. Orladeyo is an oral therapy, taken once a day, to prevent swelling attacks with hereditary angioedema (HAE). Er-Kim, based in Istanbul, partners with pharma companies to bring new therapies to markets around…